Pfizer Global Medical Grants RFP: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Research in Canada

Well-being, Health and Biomedical Discovery


Academic Unit: inquire with unit

Memorial Deadline: Thursday 2nd, June 2022

External Deadline: Tuesday 7th, June 2022


Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP.

Date RFP Issued: March 24, 2022

Geographic Scope: Canada

Clinical Area: Transthyretin Amyloid Cardiomyopathy

Link to full RFP: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Research in Canada

Application Due Date: June 7, 2022

Specific Area of Interest: Projects that will be considered for Pfizer support will focus on:

  • – Early identification, evaluation, diagnosis, prognosis & treatment
  • – Epidemiology (prevalence of TTR amyloidosis among at-risk populations [e.g. carpal tunnel syndrome, aortic stenosis, hypertrophic cardiomyopathy, lumbar spinal stenosis, hip & knee arthroplasty, atrial fibrillation])
  • – Scintigraphy (use of scintigraphy for diagnosis of early disease and/or monitoring disease progression; phenotype and management of patients with Perugini Grade 1 uptake)
  • – Post organ transplant (use of tafamidis; natural course of disease)
  • – Mixed phenotypic manifestations (e.g. polyneuropathy and cardiomyopathy)
  • – Longitudinal evaluations of neurologic manifestations in patients with ATTR-CM including wild type
  • – Development of new quality of life measures or patient report outcomes measures in ATTR amyloidosis
  • – New methodology to accelerate appropriate ATTR CM patient identification including Machine learning/ Artificial Intelligence and new biomarkers
  • – Use of tafamidis in the clinical setting (i.e. real world evidence)
    – Functional role of TTR in humans or non-human primates

Funding Sources

Pfizer Inc

This opportunity was posted by: RGCS

Last modified: March 24, 2022